Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. Undoubtedly, this has played a factor in the success of market-leading PD-1 inhibitors, Merck & Co.’s million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130

Antibody DNA Development Vaccination 130

pharmaphorum

OCTOBER 29, 2021

Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. Analysts welcomed the performance but also noted it points to underlying weakness at the company.

Trials 52

Trials Sales FDA Approval Production 52

pharmaphorum

APRIL 5, 2022

The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.

Sales 52

Sales Protein Drugs Trials 52

pharmaphorum

JANUARY 5, 2021

First-line immunotherapy for NSCLC is dominated by Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab), transforming the prospects of some patients and propelling the drug to multibillion-dollar sales. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

XTalks

AUGUST 17, 2020

Co-stimulatory second signal – the signal consists of two molecules of IL-2 on either end of the compound. The co-stimulatory IL-2 signal is the same for all of the 100 series molecules (i.e. HPV E7 peptide – this targets HPV-specific T cells, as the tumors are transformed by HPV and express the viral E7 protein. 101, 102, 103).

Protein 98

Protein Engineer Immune Response In-Vivo 98